CAS 1505515-69-4

Taletrectinib

CAS: 1505515-69-4

3-(4-((R)-2-Aminopropoxy)phenyl)-N-((R)-1-(3-fluorophenyl)ethyl)imidazo[1,2-b]pyridazin-6-amine adipate

Formula: C₂₉H₃₄FN₅O₅

Purity: 99%

Molecular weight: 551.61

Ref: IN-DG01163724

Taletrectinib

CAS: 1505515-69-4

Taletrectinib

Formula: C₂₉H₃₄FN₅O₅

Purity: ≥98%, 10 mM in DMSO

Molecular weight: 551.61

Ref: 54-BUP03569

Taletrectinib

CAS: 1505515-69-4

Taletrectinib (AB-106) is a new-generation selective inhibitor of ROS1/NTRK including ROS1,NTRK1,NTRK2 and NTRK3.

Formula: C₂₉H₃₄FN₅O₅

Purity: 99.87% - 99.96%

Color and Shape: White Solid

Molecular weight: 551.61

Ref: TM-T22318

Taletrectinib Adipate

Controlled Product

CAS: 1505515-69-4

Formula: C₂₉H₃₄FN₅O₅

Color and Shape: Neat

Molecular weight: 551.62

Ref: TR-T757780

Taletrectinib

CAS: 1505515-69-4

Taletrectinib is a small molecule that inhibits the activity of serine proteases, including caspase-3 and cathepsin B. Taletrectinib binds to the active site of these enzymes, preventing them from cleaving their substrate proteins. It has been shown to have antitumor activity in cell cultures as well as in mice with tumors. This drug has a terminal half-life of about 6 hours in human plasma. The safety profile of taletrectinib is similar to those of other drugs used for cancer treatment. This drug has been tested in phase 1 clinical trials and demonstrated an escalation dose response effect. In addition, it demonstrated a favorable safety profile with limited toxicity profiles. Taletrectinib targets lesions on zymogens that are not accessible by other drugs such as lorlatinib or ibrutinib.br> br> Taletrectinib is also being developed for the treatment of neuroendocrine

Formula: C₂₉H₃₄FN₅O₅

Purity: Min. 95%

Molecular weight: 551.6 g/mol

Ref: 3D-FKC51569